Depot naltrexone
Phase 2Small molecule
Depot naltrexone is one of 13 small molecule programs targeting Heroin Dependence. It is currently in Phase 2.
1
Indications
5
Total Trials
0
Active Trials
12
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
14 competitors in Heroin Dependence
#DrugCompanyPhaseTrials
1Revia
TevaApproved
Minocin
TTriax
Approved
Buprenorphine/naloxone
AstellasApproved
Narcan
SScienture
Approved
Suboxone
IIndivior Inc.
Approved
Catapres
Boehringer IngelheimApproved
Remeron
OOrganon and Co
Approved
Lucemyra
BBioCorRx Pharmaceuticals Inc
Approved
Dolophine
HHikma Pharmaceuticals LLC
Approved
Namenda
AbbViePhase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Treatment2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Depot naltrexone. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details